MEdical Treatment in Idiopathic Ventricular Fibrillation Patients
Key facts
- Where
- Copenhagen and Odense, DenmarkSee the 2 sites
- Phase
- Phase 4
Where in Denmark
- The Heart Center, RigshospitaletCopenhagen, DenmarkContact: Bo G Winkel, MD, PhDTaking people
- Odense University HospitalOdense, DenmarkContact: Finn L Henriksen, MDNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bo Gregers Winkel
- Trial code
- NCT07405229
- Record updated
- 1 September 2026
- Original description
A person who has experienced a cardiac arrest with no apparent cause is at risk of having recurrent cardiac arrest. Hence an implantable cardioverter-defibrillator (ICD) is recommended on empirical grounds. Today, there is no uniform way of approaching prevention of recurrence in idiopathic ventricular fibrillation (IVF) patients, beside ICD implantation. Better reatment and risk stratification tools are needed Medical treatment in these patients has never been assessed systematically, but at least some patients with no apparent diagnosis are on betablocker treatment. It is not known if low-doselow dose betablocker treatment is beneficial in these patients.Read full original descriptionShow less
Investigation of RIsk Factors in Out-of-hospital-cardiac-arrest Patients, and MEdical Treatment in Idiopathic Ventricular Fibrillation Patients
A person who has experienced a cardiac arrest with no apparent cause is at risk of having recurrent cardiac arrest. Hence an implantable cardioverter-defibrillator (ICD) is recommended on empirical grounds. Today, there is no uniform way of approaching prevention of recurrence in idiopathic ventricular fibrillation (IVF) patients, beside ICD implantation. Better reatment and risk stratification tools are needed Medical treatment in these patients has never been assessed systematically, but at least some patients with no apparent diagnosis are on betablocker treatment. It is not known if low-doselow dose betablocker treatment is beneficial in these patients.
This study investigates the effect of betablocker treatment to reduce arrhythmic burden in IVF patients.
No predictors for appropriate ICD therapy have been identified in patients with IVF. It is also explored if toxicological and/or genetic profiles, together with in depth machine learning simulation data on repolarization patterns from IVF-ECGs compared to controls, can be used as risk stratification tools.
Lastly, QOL in IVF patients and the impact of beta blocker treatment will be investigated.
Inclusion: Resuscitated OHCA patients admitted to one of the participating hospitals; Age ≥18 years; Suspected cardiac cause of cardiac arrest.
Exclusion: With Ischemic heart disease; Obvious non-cardiac cause of cardiac arrest; Congenital heart disease; OHCA patients; Do not speak or understand Danish; Foreigners -.